Nasdaq signal

Nice little rise of 5% overnight [on tiny volume] . The six month trend is very strong - rising with the company's new narrative of a "restoration" phase [Greg West, 2017] leading to a company with two clinical trials to be well underway before year-end. Funding is a fait accompli. Jerel Banks used to manage a fund worth billions and is now the investment chief of Nant. Believe me gentlemen - this is the stealth phase of strategic planning [promises of cheap options to Roth & co] and preparation [articulation of new orphan disease targets]. Announcements imminent. With moderate volume the share price will rise 500% in days.